Converging technologies to increase drug and vaccine safety and effectiveness.

A group of internationally recognized researchers from universities and business are cooperating in the MEDINTECH project to create an Italian technological platform aimed at developing research on new molecules for preventing infection and treating autoimmune disease.

Thanks to a specific development project for a new biodrug to treat genetic eye diseases, this project has considerable industrial value. Alongside research and development activities, young researchers will be involved in a highly specialized training process giving them basic as well as applied scientific knowledge, thus preparing them for jobs in the biomedical industry. R&D activities will be part of a wider prevention and treatment strategy that will focus on safe-by-design pharmacology to achieve customized treatment.

Project Leader: Novartis

Partners: Dompè, Axxam, Charybdis, Primm, ViroStatics, Consiglio Nazionale delle Ricerche, Istituto Nazionale di Genetica Molecolare, Università degli Studi di Milano, Università di Firenze, Università di Roma La Sapienza

Project Manager: Ugo D’Oro (Novartis)

Accounting Manager: Francesco Siciliano (Novartis) – Aldo Tagliabue (Alta)

Training Manager: Ugo D’Oro (Novartis)